23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Företagslösning
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Välkommen till vår företagslösning

    Här kan du administrera användarna i din företagslösning.

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
News in English

After the threat of tariffs – Novartis invests 230 billion in the USA

Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines destined for the US market to be produced within the country.

The Swiss company will invest in ten manufacturing and research facilities in the USA, of which seven are brand new. The initiative is expected to create 1,000 new jobs at Novartis and generate an additional 4,000 jobs in the USA, according to a press release from the company.

Among other things, a new research hub is planned in San Diego, where the company hopes to attract leading American researchers. Four new production facilities will be built—threethat will make biologics drug substances, drug products, device assembly and packaging, and 1 facility that will make chemical drug substances, oral solids dosage forms and packaging.

BREAKING
{{ article.headline }}
0.188|